Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over

  • Technology appraisal guidance
  • TA1093
  • Published: 
Download guidance (PDF)

2 Information about Idebenone

Marketing authorisation indication

2.1

Idebenone (Raxone, Chiesi) is indicated for the 'treatment of visual impairment in adolescent and adult patients with Leber's hereditary optic neuropathy (LHON)'.

Dosage in the marketing authorisation

Price

2.3

The list price for a 180 tablets pack of 150 mg idebenone is £6,364 (excluding VAT; BNF online, accessed April 2024).

2.4

The company has a commercial arrangement. This makes idebenone available to the NHS at a discount. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.5

For information, Chiesi did not disclose its Carbon Reduction Plan for UK carbon emissions.